Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity.

Korioth-Schmitz B, Perley CC, Sixsmith JD, Click EM, Lee S, Letvin NL, Frothingham R.

Vaccine. 2015 Oct 13;33(42):5715-5722. doi: 10.1016/j.vaccine.2015.07.010. Epub 2015 Jul 17.

2.

Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors.

Hart BE, Asrican R, Lim SY, Sixsmith JD, Lukose R, Souther SJ, Rayasam SD, Saelens JW, Chen CJ, Seay SA, Berney-Meyer L, Magtanong L, Vermeul K, Pajanirassa P, Jimenez AE, Ng TW, Tobin DM, Porcelli SA, Larsen MH, Schmitz JE, Haynes BF, Jacobs WR Jr, Lee S, Frothingham R.

Clin Vaccine Immunol. 2015 Jul;22(7):726-41. doi: 10.1128/CVI.00075-15. Epub 2015 Apr 29.

3.

Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells.

Venkataswamy MM, Ng TW, Kharkwal SS, Carreño LJ, Johnson AJ, Kunnath-Velayudhan S, Liu Z, Bittman R, Jervis PJ, Cox LR, Besra GS, Wen X, Yuan W, Tsuji M, Li X, Ho DD, Chan J, Lee S, Frothingham R, Haynes BF, Panas MW, Gillard GO, Sixsmith JD, Korioth-Schmitz B, Schmitz JE, Larsen MH, Jacobs WR Jr, Porcelli SA.

PLoS One. 2014 Sep 25;9(9):e108383. doi: 10.1371/journal.pone.0108383. eCollection 2014.

4.

Recombinant Mycobacterium bovis bacillus Calmette-Guérin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques.

Sixsmith JD, Panas MW, Lee S, Gillard GO, White K, Lifton MA, Balachandran H, Mach L, Miller JP, Lavine C, DeMarco CT, Tomaras GD, Gee C, Porcelli SA, Larsen MH, Frothingham R, Schmitz JE, Jacobs WR Jr, Haynes BF, Letvin NL, Korioth-Schmitz B.

Clin Vaccine Immunol. 2014 Oct;21(10):1385-95. doi: 10.1128/CVI.00324-14. Epub 2014 Jul 30.

5.

The human antibody response to the surface of Mycobacterium tuberculosis.

Perley CC, Frahm M, Click EM, Dobos KM, Ferrari G, Stout JE, Frothingham R.

PLoS One. 2014 Jun 11;9(2):e98938. doi: 10.1371/journal.pone.0098938. eCollection 2014.

6.

Reduced virulence of an extensively drug-resistant outbreak strain of Mycobacterium tuberculosis in a murine model.

Smith KL, Saini D, Bardarov S, Larsen M, Frothingham R, Gandhi NR, Jacobs WR Jr, Sturm AW, Lee S.

PLoS One. 2014 Apr 14;9(4):e94953. doi: 10.1371/journal.pone.0094953. eCollection 2014.

7.

Identification of early interactions between Francisella and the host.

Roberts LM, Tuladhar S, Steele SP, Riebe KJ, Chen CJ, Cumming RI, Seay S, Frothingham R, Sempowski GD, Kawula TH, Frelinger JA.

Infect Immun. 2014 Jun;82(6):2504-10. doi: 10.1128/IAI.01654-13. Epub 2014 Mar 31.

8.

Impact of surfactant protein D, interleukin-5, and eosinophilia on Cryptococcosis.

Holmer SM, Evans KS, Asfaw YG, Saini D, Schell WA, Ledford JG, Frothingham R, Wright JR, Sempowski GD, Perfect JR.

Infect Immun. 2014 Feb;82(2):683-93. doi: 10.1128/IAI.00855-13. Epub 2013 Nov 25.

9.

Development of an aerosol model of Cryptococcus reveals humidity as an important factor affecting the viability of Cryptococcus during aerosolization.

Springer DJ, Saini D, Byrnes EJ, Heitman J, Frothingham R.

PLoS One. 2013 Jul 23;8(7):e69804. doi: 10.1371/journal.pone.0069804. Print 2013.

10.

Infection with Francisella tularensis LVS clpB leads to an altered yet protective immune response.

Barrigan LM, Tuladhar S, Brunton JC, Woolard MD, Chen CJ, Saini D, Frothingham R, Sempowski GD, Kawula TH, Frelinger JA.

Infect Immun. 2013 Jun;81(6):2028-42. doi: 10.1128/IAI.00207-13. Epub 2013 Mar 25.

11.

Bioluminescence imaging to track bacterial dissemination of Yersinia pestis using different routes of infection in mice.

Gonzalez RJ, Weening EH, Frothingham R, Sempowski GD, Miller VL.

BMC Microbiol. 2012 Jul 24;12:147. doi: 10.1186/1471-2180-12-147.

12.

Ultra-low dose of Mycobacterium tuberculosis aerosol creates partial infection in mice.

Saini D, Hopkins GW, Seay SA, Chen CJ, Perley CC, Click EM, Frothingham R.

Tuberculosis (Edinb). 2012 Mar;92(2):160-5. doi: 10.1016/j.tube.2011.11.007. Epub 2011 Dec 21.

13.

Sampling port for real-time analysis of bioaerosol in whole body exposure system for animal aerosol model development.

Saini D, Hopkins GW, Chen CJ, Seay SA, Click EM, Lee S, Hartings JM, Frothingham R.

J Pharmacol Toxicol Methods. 2011 Mar-Apr;63(2):143-9. doi: 10.1016/j.vascn.2010.09.002. Epub 2010 Sep 16.

14.

Validation of an Animal Isolation Imaging Chamber for Use in Animal Biosafety Level-3 Containment.

Alderman TS, Frothingham R, Sempowski GD.

Appl Biosaf. 2010;15(2):62-66.

15.

Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates.

Larsen MH, Biermann K, Chen B, Hsu T, Sambandamurthy VK, Lackner AA, Aye PP, Didier P, Huang D, Shao L, Wei H, Letvin NL, Frothingham R, Haynes BF, Chen ZW, Jacobs WR Jr.

Vaccine. 2009 Jul 23;27(34):4709-17. doi: 10.1016/j.vaccine.2009.05.050. Epub 2009 Jun 2.

16.

Association between 16S-23S internal transcribed spacer sequence groups of Mycobacterium avium complex and pulmonary disease.

Stout JE, Hopkins GW, McDonald JR, Quinn A, Hamilton CD, Reller LB, Frothingham R.

J Clin Microbiol. 2008 Aug;46(8):2790-3. doi: 10.1128/JCM.00719-08. Epub 2008 Jun 11.

17.

The evolution of drug resistance in Mycobacterium tuberculosis: from a mono-rifampin-resistant cluster into increasingly multidrug-resistant variants in an HIV-seropositive population.

Bifani P, Mathema B, Kurepina N, Shashkina E, Bertout J, Blanchis AS, Moghazeh S, Driscoll J, Gicquel B, Frothingham R, Kreiswirth BN.

J Infect Dis. 2008 Jul 1;198(1):90-4. doi: 10.1086/588822.

PMID:
18498237
18.

Study of the role of CCR5 in a mouse model of intranasal challenge with Yersinia pestis.

Styer KL, Click EM, Hopkins GW, Frothingham R, Aballay A.

Microbes Infect. 2007 Jul;9(9):1135-8. Epub 2007 May 3.

19.

Science and security. Practical experiences in dual-use review.

Davidson EM, Frothingham R, Cook-Deegan R.

Science. 2007 Jun 8;316(5830):1432-3. No abstract available.

PMID:
17556571
20.

Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites.

Yu JS, Peacock JW, Jacobs WR Jr, Frothingham R, Letvin NL, Liao HX, Haynes BF.

Clin Vaccine Immunol. 2007 Jul;14(7):886-93. Epub 2007 May 16.

21.

Generation of mucosal anti-human immunodeficiency virus type 1 T-cell responses by recombinant Mycobacterium smegmatis.

Yu JS, Peacock JW, Vanleeuwen S, Hsu T, Jacobs WR Jr, Cayabyab MJ, Letvin NL, Frothingham R, Staats HF, Liao HX, Haynes BF.

Clin Vaccine Immunol. 2006 Nov;13(11):1204-11. Epub 2006 Aug 30.

22.

Glucose homeostasis abnormalities associated with use of gatifloxacin.

Frothingham R.

Clin Infect Dis. 2005 Nov 1;41(9):1269-76. Epub 2005 Sep 28.

PMID:
16206101
23.

Current issues in global tuberculosis control.

Frothingham R, Stout JE, Hamilton CD.

Int J Infect Dis. 2005 Nov;9(6):297-311. Epub 2005 Sep 23. Review.

24.

Yersinia pestis kills Caenorhabditis elegans by a biofilm-independent process that involves novel virulence factors.

Styer KL, Hopkins GW, Bartra SS, Plano GV, Frothingham R, Aballay A.

EMBO Rep. 2005 Oct;6(10):992-7.

25.

Chlamydia pneumoniae and acute coronary syndrome.

Frothingham R.

N Engl J Med. 2005 Aug 4;353(5):525-8; author reply 525-8. No abstract available.

PMID:
16080249
26.

Nasal peptide vaccination elicits CD8 responses and reduces viral burden after challenge with virulent murine cytomegalovirus.

Gopal IN, Quinn A, Henry SC, Hamilton JD, Staats HF, Frothingham R.

Microbiol Immunol. 2005;49(2):113-9.

27.

Non-O1 Vibrio cholerae septicemia: case report, discussion of literature, and relevance to bioterrorism.

Anderson AM, Varkey JB, Petti CA, Liddle RA, Frothingham R, Woods CW.

Diagn Microbiol Infect Dis. 2004 Aug;49(4):295-7.

PMID:
15313536
28.

"Me-too" products--friend or foe?

Frothingham R.

N Engl J Med. 2004 May 13;350(20):2100-1; author reply 2100-1. No abstract available.

PMID:
15141054
29.

Quinolone safety and efficacy more important than potency.

Frothingham R.

Emerg Infect Dis. 2004 Jan;10(1):156-7. No abstract available.

30.

Racial differences in hepatitis B and hepatitis C and associated risk behaviors in veterans with severe mental illness.

Butterfield MI, Bosworth HB, Stechuchak KM, Frothingham R, Bastian LA, Meador KG, Swartz M, Horner RD.

J Natl Med Assoc. 2004 Jan;96(1):43-52.

31.

Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia.

Frothingham R.

Clin Infect Dis. 2002 Oct 1;35(7):896-7; author reply 897-8. No abstract available.

PMID:
12228830
32.

In vivo protein expression and immune responses generated by DNA vaccines expressing mycobacterial antigens fused with a reporter protein.

Quinn A, Jiang W, Velaz-Faircloth M, Cobb AJ, Henry SC, Frothingham R.

Vaccine. 2002 Aug 19;20(25-26):3187-92.

PMID:
12163270
33.

Identification and evolution of an IS6110 low-copy-number Mycobacterium tuberculosis cluster.

Mathema B, Bifani PJ, Driscoll J, Steinlein L, Kurepina N, Moghazeh SL, Shashkina E, Marras SA, Campbell S, Mangura B, Shilkret K, Crawford JT, Frothingham R, Kreiswirth BN.

J Infect Dis. 2002 Mar 1;185(5):641-9. Epub 2002 Feb 14.

PMID:
11865421
34.
35.

Molecular identification of streptomycin monoresistant Mycobacterium tuberculosis related to multidrug-resistant W strain.

Bifani P, Mathema B, Campo M, Moghazeh S, Nivin B, Shashkina E, Driscoll J, Munsiff SS, Frothingham R, Kreiswirth BN.

Emerg Infect Dis. 2001 Sep-Oct;7(5):842-8.

36.

Quinolones for community-acquired pneumonia.

Frothingham R.

Arch Intern Med. 2001 Jul 9;161(13):1681-2. No abstract available.

PMID:
11434807
37.

Mortality rates in comparative trials of formulations of amphotericin B.

Frothingham R.

Clin Infect Dis. 2001 Aug 15;33(4):582-3. No abstract available.

PMID:
11462201
38.

Mycobacteria: treatment approaches and mechanisms of resistance.

Frothingham R.

J Med Liban. 2000 Jul-Aug;48(4):248-54. Review.

PMID:
11214197
39.

Rapid identification of laboratory contamination with Mycobacterium tuberculosis using variable number tandem repeat analysis.

Gascoyne-Binzi DM, Barlow RE, Frothingham R, Robinson G, Collyns TA, Gelletlie R, Hawkey PM.

J Clin Microbiol. 2001 Jan;39(1):69-74.

40.

Molecular epidemiology and tuberculosis control

Bifani PJ, Shopsin B, Alcabes P, Mathema B, Kreiswirth BN, Liu Z, Driscoll J, Frothingham R, Musser JM.

JAMA. 2000 Jul 19;284(3):305-7. No abstract available.

PMID:
10891955
41.

Evaluation of the accuracy and reproducibility of a practical PCR panel assay for rapid detection and differentiation of Mycobacterium avium subspecies.

Ellingson JL, Stabel JR, Bishai WR, Frothingham R, Miller JM.

Mol Cell Probes. 2000 Jun;14(3):153-61.

PMID:
10860713
42.

Identification of a W variant outbreak of Mycobacterium tuberculosis via population-based molecular epidemiology.

Bifani PJ, Mathema B, Liu Z, Moghazeh SL, Shopsin B, Tempalski B, Driscol J, Frothingham R, Musser JM, Alcabes P, Kreiswirth BN.

JAMA. 1999 Dec 22-29;282(24):2321-7.

PMID:
10612319
43.
44.

Complex transmission dynamics of clonally related virulent Mycobacterium tuberculosis associated with barhopping by predominantly human immunodeficiency virus-positive gay men.

Yaganehdoost A, Graviss EA, Ross MW, Adams GJ, Ramaswamy S, Wanger A, Frothingham R, Soini H, Musser JM.

J Infect Dis. 1999 Oct;180(4):1245-51.

PMID:
10479154
45.

Protection against Mycobacterium avium by DNA vaccines expressing mycobacterial antigens as fusion proteins with green fluorescent protein.

Velaz-Faircloth M, Cobb AJ, Horstman AL, Henry SC, Frothingham R.

Infect Immun. 1999 Aug;67(8):4243-50.

46.

Comparison of methods based on different molecular epidemiological markers for typing of Mycobacterium tuberculosis complex strains: interlaboratory study of discriminatory power and reproducibility.

Kremer K, van Soolingen D, Frothingham R, Haas WH, Hermans PW, Martín C, Palittapongarnpim P, Plikaytis BB, Riley LW, Yakrus MA, Musser JM, van Embden JD.

J Clin Microbiol. 1999 Aug;37(8):2607-18.

47.

The GroES antigens of Mycobacterium avium and Mycobacterium paratuberculosis.

Cobb AJ, Frothingham R.

Vet Microbiol. 1999 Jun 1;67(1):31-5.

PMID:
10392775
48.
49.

Phenotypic and genotypic characterization of Mycobacterium africanum isolates from West Africa.

Frothingham R, Strickland PL, Bretzel G, Ramaswamy S, Musser JM, Williams DL.

J Clin Microbiol. 1999 Jun;37(6):1921-6.

50.

AIDS exceptionalism.

Frothingham R.

Ann Intern Med. 1999 Jan 5;130(1):80. No abstract available.

PMID:
9890869

Supplemental Content

Loading ...
Support Center